The impact of chronic obstructive pulmonary disease and hypertension on the development and progression of atrial fibrillation
https://doi.org/10.15829/1728-8800-2019-5-138-144
Abstract
The article presents a review of the literature, reflecting ideas about the effect of chronic obstructive pulmonary disease on the development and progression of atrial fibrillation. Modern concepts regarding the substrate and triggers of paroxysms of atrial fibrillation have recently changed significantly. The role of concomitant diseases, in particular arterial hypertension and chronic obstructive pulmonary disease, formed the basis for changes in the electrophysiological properties of the myocardium.
About the Authors
L. D. Khidirova
Novosibirsk State Medical University
Russian Federation
Russian Federation
D. A. Yakhontov
Novosibirsk State Medical University
Russian Federation
Russian Federation
S. A. Zenin
Novosibirsk Regional Cardiology Clinical Dispensary
T. S. Kuropii
Novosibirsk State Medical University
Russian Federation
Russian Federation
References
1. Chazov EI, Golitsyna SP. Guide to Cardiac Arrhythmias. М: Geotar-Media, 2010. 23299 р. (in Russ.) ISBN: 5970416436, 9785970416433.
2. Lebedev DI, Krivolapov SN, Zavadovsky KV, et al. Diagnosis and treatment of atrial fibrillation. Russian Journal of Cardiology. 2017;(7):7-86. (In Russ.). doi:10.15829/1560-4071-2017-7-7-86.
3. Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;16(2):1-3. doi:10.1016/j.ejim.2018.05.016.
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
5. Weijs B, Pisters R, Nieuwlaat R, et al. Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace. 2012;14(2):184-90. doi:10.1093/europace/eur379.
6. Hisashi O, Yoshimori An, level A, et al. Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse. Events stroke. October 2018;49:100-16. http://www.umin.ac.jp/ctr.
7. Clarke R, Lewington S. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet Glob Health. 2018;6(6):641-9. doi:10.1016/S2214-109X(18)30217-1.
8. Mathers CD, Loncar DP, Lo S. Projections of Global Mortality and Burden of Disease. Medicine. 2017;8:209-24. doi:10.21037/jtd.2016.07.07.
9. Malysh EYu, Drobysheva YeS, Chernov AV. Chronic obstructive lung disease and damage to the cardiovascular system. Young Scientist. 2014; 5:145-8. (In Russ.)
10. Lip G, Coca А. A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE) 6. doi:10.1093/europace/eux091. (19 June 2017).
11. Pokushalov E, Romanov A, Corbucci G, et al. Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study. Circ Arrhythm Electrophysiol. 2011;4(6):823-31. doi:10.1161/CIRCEP.111.964809.
12. Renate B, Schnabel, Xiaoyan Yin, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Published 2015 in Lancet. doi:10.24022/1997-3187-2018-12-1-31-39.
13. Apostolakis S, Sullivan R. Left ventricular geometry and outcomes in patients with atrial fibrillation: the AFFIRM Trial. Int J Cardiol. 2014;170(3):3038-63. doi:10.1016/j.ijcard.201311.002.
14. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011 Jan 11;57(2):223-42. doi:10.1016/j.jacc.2010.10.001. Epub 2010 Dec 21.
15. Padfield GJ, Steinberg C, Swampillai J, et al. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm. 2017;14(6):801-07 doi:10.1016/j.hrthm.2017.01.038.
16. De Vos CB, Breithardt G, Camm AJ, et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-ontroltherapy. Am Heart J. 2012;163(5):887-93. doi:10.1016/j.ahj.2012.02.015.
17. Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilatator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest. 2012;142(2):298-304. doi:10.1378/chest.10-2499.
18. Huang B, Yang Y. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc. 2014;15(8):576-81. doi:10.1016/j.jamda.2014.04.009.
19. Leonova EI, Shehyan GG, Zadionchenko VS, et al. Atrial fibrillation in patients with 40. chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2014;10(3):328-33. (In Russ.) doi:10.20996/1819-6446-2014-10-3-328-333.
20. Grigoryan SV, Azarapetyan LG, Adamyan KG. Comparative evaluation of markers of inflammation and fibrosis in patients with various clinical forms of atrial fibrillation. Cardiovascular Therapy and Prevention. 2018;17(6):26-31. (In Russ.) doi:10.15829/1728-8800-2018-6-26-31.
21. Pavlova V, Kichigin V, Madyanov I. Adrenacortical hormone rate in blood of patients 45. ill with chronic obstructive pulmanory disease. J Health Care of Chuvashia. 2012;5(4):324-51. (In Russ.)
22. Kashuro VA, Dolgo-Saburov VB, Basharin VA, et al. Mechanisms of violation of bioenergy and optimization of approaches to their pharmacotherapy. Pharmacology. 2010;11 (6):611-26. (In Russ.)
23. Laghi V, Adiguzel N, Tobin M. Endocrinological derangements in COPD. Eur Respiratory J. 2009; 34:975-96. doi:10.1183/09031936.00103708
24. Trip P1, Nossent EJ, de Man FS, et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension. Patient characteristics and treatment 48. responses. 2013;42(6):1575-85. doi:10.1183/09031936.00184412.
25. Terzano C, Romani S, Conti V, et al. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014;18(19):2908-17 doi: 49. 10.1016/j.trsl.2013.05.001.
26. Camm AJ. focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. 50. Europace. 2012;14(10):1385-413. doi:10.1093/eurheartj/2Fehs253.
27. Melnichenko OV, Nekrasov AA, Kuznetsov AN. Factors Associated with the Development of Atrial Fibrillation in Chronic Obstructive Pulmonary Disease. IJBM 51. 2011;1(2):71-83. doi:10.20996/1819-6446-2016-12-1-26-30.
28. Dodouras T, Paraskevaidis IA. Prediction of successful cardioversion and maintenance 52. of sinus rhythm in patients with lone atrial fibrillation. Chest. 2015;127(2):488-94. doi:10.1378/chest.127.2.488.
29. Ying-Shuo Huang, Ying-Chao Feng, Feng YC, et al. Impact of chronic obstructive 53. pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients. Clin Interv Aging. 2015; 10:81-7. doi:10.2147/CIA.S71878.
30. Tomoko I, Brenda K. Atrium Fibrosis and Inflammation: Impaired Atrial Natriuretic 54. Peptide System in Experimental. Heart Failure Originally. 2018; 1:232-45. doi:10.1155/2018/7279036.
31. Heeringa J, van der Kuip DA, Hofman A, et al. Subclinical atherosclerosis and risk of 55. atrial fibrillation: the Rotterdam study. Arch Intern Med. 2007 Feb 26;167(4):382-7.
32. Bunch TJ, Day JD, Olshansky B, et al. Newly detected atrial fibrillation in patients with an implantable cardioverterdefibrillator is a strong risk marker of increased mortality. 56. Heart Rhythm. 2009; 6:2-8. doi:10.1016/j.hrthm.2008.09.025.
33. Verdejo H, Roldan J, Bae BS, et al. Systemic vascular cell adhesion molecule-1 predicts the occurrence of post-operative atrial fibrillation. Int J Cardiol. 2011;150(3):270-6. doi: 10.1016/j.ijcard.2010.04.033.
34. Gray L, Lee IM, Sesso H.D, et al. Blood pressure in early adulthood, hypertension 57. in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study). JACC. 2011;58(23):2396-03.
35. Vatutin NT, Sklyanna EV. Prevalence of arterial hypertension and risk factors 58. in young adults. The Russian Archives of Internal Medicine. 2017;7( 1):30-4. (In Russ.) doi:10.20514/2226-6704-2017-7-1-30-34.
36. ESC/ESH Guidelines for the management of arterial hypertension were presented at 60. the 28th Scientific Meeting of the European Society of Hypertension in Barcelona. 2018. http://www.eshonline.org/guidelines/arterial-hypertension/.
37. Conen D, Tedrow UB, Koplan BA, et al. Influence of systolic and diastolic blood 61. pressure on the risk of incident atrial fibrillation. Circulation. 2009;28;119(16):2146-52. doi:10.1161/CIRCULATIONAHA.108.830042.
38. Toh, N, Kanzaki, H, Nakatani S, et al. Left atrial volume combined with atrial pump function identifies hypertensive patients with a history of 62. paroxysmal atrial fibrillation. Hypertension. 2010;55(5):1150-6. doi:10.1161/HYPERTENSIONAHA.109.137760.
39. Zholbayeva А, Golukhova Е, Tabina А. Molecular mechanisms of atrial fibrillation: 63. „ideal” marker searching. Creative Cardiology J. 2015;12:152-61. doi: 10.15275/kreatkard.2015.02.04.
40. Dzeshka MS, Lip GY, Snezhitskiy V, et al. Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. JACC. 2015;66(8):943-59. doi:10.1016/j.jacc.2015.06.1313.
41. Aldhoon B, Melenovsk V, Peichl P, et al. New insights into mechanisms of atrial fibrillation. Physiol Res. 2010;59(1):1-12. doi:10.1155/2013/637482.
42. Gaita F, Blandino A. Atrial fibrillation. Left atrial fibrosis — a promising stroke risk factor? Nat Rev Cardiol. 2011;8(6):307-8. doi:101038/nrcardio.2011.63.
43. Huerta A, Lоpez B. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. J Hypertens. 2016;34(1):130-8. doi:10.1097/HJH.0000000000000757.
44. McMurray MD, Trivax JE, McCullough PA. Serum cystatin C, renal filtration function, and left ventricular remodelingirc Heart Fail. 2009;2(2):86-9. doi:10.15829/1560-4071-2018-1-14-20.
45. Lifang X, Jerome T, et al. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res. 2010;87(4):628-35. doi:101093/2Fcvr/2Fcvq138.
46. Surovtseva MV. Remodeling of the heart and vessels in atrial fibrillation patients with chronic heart failure according to cystatin c-related glomerular filtration rate. Russian Journal of Cardiology. 2018;(1):14-20. (In Russ.) doi:10.15829/1560-4071-2018-1-14-20
47. Alkhiary W, Abdalaal M, El-Sabbagh A. Serum Concentrations of Interleukin-33 and its Soluble Receptor sST2 in Patients withPersistent Atrial Fibrillation. J Mol Biomark Diagn. 2015;6:235-42.
48. Marcus GM, Smith LM, Ordovas K, et al. Intracardiac and extracardiac markers of inflammation duringatrial fibrillation. Heart Rhythm. 2010;7:149-54. doi:10.1016/j.hrthm.2009.10.004.
49. Sasaki N, Okumura Y, Watanabe I, et al. Increased levels of inflammatory and extracellular matrix turnoverbiomarkers persist despite reverse atrial structural remodeling during thefirst year after atrial fibrillation ablation. J Interv Card Electrophysiol. 2014;39:241-9. doi:10.1007/s10840-013-9867-6.
50. Corradi D, Callegari S, Manotti L, et al. Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. Heart Rhythm. 2014;11:1250-8. doi:101016/j.hrthm.2014.02.008.
51. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011 ;8:22. doi:10.1186/1476-9255-8-22.
52. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc. Res. 2011;89(4).744-53. doi:10.1093/cvr/cvq329.
53. Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Clin Res Cardiol. 2014;94(11):1458-65. doi:10.1161/01.RES.0000129579.59664.9d.
54. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016; Available from: https://goldcopd.org/ (11 may 2016).
55. Mazen K, George W. Booz New take on the role of angiotensin ii in cardiac hypertrophy and fibrosis. Hypertension. 2011;57(6):1034-8. doi:10.1161%2Fhypert ensionaha.111.172700.
56. Drapkina OM, Emelyanov AV. Atrial fibrosis is the morphological basis of atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2013;9(4):417-22. (In Russ.) doi:10.15829/1560-4071-2018-9-71-76.
57. Xu J, Carretero OA, Liao TD, et al. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol. 2010;299(5):1328-38. doi:10.1152/ajpheart.00538.2010.
58. Friedrichs K, Baldus S, Klinke A. Fibrosis in atrial fibrillation — role of reactive species and MPO. Front Physio. 2012;3:214-25. doi:10.3389/fphys.2012.00214.
59. Huang XR, Chung AC, et al. Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. Hypertension. 2010;55(5):1165-71. doi:10.1161/HYPERTENSIONAHA.109.147611.
60. Tanabe Y, Kawamura Y, Sakamoto N, et al. Blood pressure control and the reduction of left atrial oveload is essential for controlling atrial fibrillation. Int Heart J. 2009;50(4)445-56. doi:10.1155/2014/980505.
61. Grigoryan SV, Azarapetyan LG, Adamyan KG. Myocardial fibrosis and atrial fibrillation. Russian Journal of Cardiology. 2018;(9):71-6. (In Russ.) doi:10.15829/1560-4071-2018-9-71-76.
62. Lavall D, Selzer C, Schuster P, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. JACC. 2014;289(10):6656-68. doi:101074/jbc.M113.519256.
63. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. 2013;168(6):5135-42. doi:101016/j.ijcard.2013.
Review
For citations:
Khidirova L.D., Yakhontov D.A., Zenin S.A., Kuropii T.S. The impact of chronic obstructive pulmonary disease and hypertension on the development and progression of atrial fibrillation. Cardiovascular Therapy and Prevention. 2019;18(5):138-144. (In Russ.) https://doi.org/10.15829/1728-8800-2019-5-138-144
Views:
752
Email this article 
